Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 3/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2189636 | 0.91 | F2 (0.43) | F2BACE1BACE2MMEACE | |
| SCHEMBL29972923 | 0.85 | NAALAD2 (0.53) | F2BACE1BACE2MMEACE | |
| SCHEMBL29458786 | 0.83 | ACE (0.51) | OPRD1KISS1RF2BACE1BACE2 | |
| SCHEMBL11886068 | 0.83 | ACE (0.51) | OPRD1KISS1RF2BACE1BACE2 | |
| SCHEMBL29857400 | 0.83 | ACE (0.51) | OPRD1KISS1RF2BACE1BACE2 | |
| SCHEMBL17915899 | 0.83 | ACE (0.48) | OPRD1KISS1RF2BACE1BACE2 | |
| SCHEMBL31278149 | 0.82 | ACE (0.53) | BACE1BACE2MMEACECPA1 | |
| SCHEMBL29624265 | 0.82 | KISS1R (0.52) | OPRD1KISS1RBACE1MMEACE | |
| SCHEMBL29413128 | 0.82 | KISS1R (0.51) | OPRD1KISS1RBACE1 | |
| SCHEMBL29892885 | 0.80 | NAALAD2 (0.51) | OPRD1BACE1BACE2MMEENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | OPRD1 3100/4885KISS1R 1433/4885F2 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.